Related references
Note: Only part of the references are listed.The Immunological Synapse: A Molecular Machine Controlling T Cell Activation
Arash Grakoui et al.
JOURNAL OF IMMUNOLOGY (2015)
The actin cytoskeleton in T cell activation
Janis K. Burkhardt et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
Alessandra Ferrajoli et al.
BLOOD (2008)
CC-4047 promotes Th1 cell differentiation and reprograms polarized human Th2 cells by enhancing transcription factor T-bet
Weiming Xu et al.
CLINICAL IMMUNOLOGY (2008)
Lenalidomide for the treatment of B-cell malignancies
Asher A. Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia
Leslie A. Andritsos et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G
G. Maki et al.
LEUKEMIA (2008)
Thalidomide analogues as anticancer drugs
Jeanny B. Aragon-Ching et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2007)
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells
Dominique Verhelle et al.
CANCER RESEARCH (2007)
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study
Asher Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Paul G. Richardson et al.
BLOOD (2006)
Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly
AK Gandhi et al.
LEUKEMIA RESEARCH (2006)
Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-θ activation and enhancing the DNA-binding activity of AP-1 but not NF-κB, OCT-1, or NF-AT
F Payvandi et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2005)
Efficacy of lenalidomide in myelodysplastic syndromes
A List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Thalidomide as a novel therapeutic agent: new uses for an old product
SK Teo et al.
DRUG DISCOVERY TODAY (2005)
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
T Hayashi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents
JB Bartlett et al.
NATURE REVIEWS CANCER (2004)
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway
R LeBlanc et al.
BLOOD (2004)
Rational design and characterization of a Rac GTPase-specific small molecule inhibitor
Y Gao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Cell migration: Integrating signals from front to back
AJ Ridley et al.
SCIENCE (2003)
CD28-mediated co-stimulation: A quantitative support for TCR signalling
O Acuto et al.
NATURE REVIEWS IMMUNOLOGY (2003)
Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs
PH Schafer et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Rocks: Multifunctional kinases in cell behaviour
K Riento et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Rho GTPases in cell biology
S Etienne-Manneville et al.
NATURE (2002)
Spatial and temporal analysis of Rac activation during live neutrophil chemotaxis
EM Gardiner et al.
CURRENT BIOLOGY (2002)
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
FE Davies et al.
BLOOD (2001)
Control of pre-T cell proliferation and differentiation by the GTPase Rac-I
M Gomez et al.
NATURE IMMUNOLOGY (2000)
Share Paper
